Laguna Bio unveiled a microbial immunotherapy program that engineers an attenuated Listeria monocytogenes strain to stimulate multifactorial immune responses against cancer. Founders Jonathan Kotula, Dan Portnoy, and Russell Carrington are advancing the lead strain toward clinical testing in pediatric leukemia. The company argues engineered microbes can engage rare γδ T cells and broader innate pathways that conventional reductionist immunotherapies may miss. Laguna plans early‑phase trials to test safety and durability in pediatric patients while leveraging decades of Listeria biology expertise. Regulatory and safety scrutiny will be paramount given the use of a live bacterial platform; the team emphasizes extensive attenuation and control measures. If safe and immunogenic, the approach could open a new class of living cancer therapeutics.